Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs

被引:66
作者
Song, Gina [1 ]
Wu, Huali [1 ]
Yoshino, Keisuke
Zamboni, William C. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ N Carolina, Div Pharmacotherapy & Expt Therapeut, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Mol Therapeut Program, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, UNC Inst Pharmacogen & Individualized Therapy, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Carolina Ctr Canc Nanotechol Excellence, Chapel Hill, NC 27599 USA
[5] N Carolina Biomedial Innovat Network, Chapel Hill, NC USA
关键词
pharmacokinetics; pharmacodynamics; liposomes; STERICALLY STABILIZED LIPOSOMES; TEMPERATURE-SENSITIVE LIPOSOMES; LARGE UNILAMELLAR LIPOSOMES; HUMAN TUMOR XENOGRAFT; PHASE-II TRIAL; IN-VIVO; POPULATION PHARMACOKINETICS; PROLONGED CIRCULATION; POLYETHYLENE-GLYCOL; CKD-602; S-CKD602;
D O I
10.3109/08982104.2012.655285
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Various attempts to increase the therapeutic index of the drug while minimizing side effects have been made in drug delivery systems. Among several promising strategies, liposomes represent an advanced technology to target active molecules to the site of action. Rapid clearance of circulating liposomal drugs administered intravenously has been a critical issue because circulation time in the blood affects drug exposure at the target site. The clinical use of liposomal drugs is complicated by large intra-and interindividual variability in their pharmacokinetics (PK) and pharmacodynamics (PD). Thus, it is important to understand the factors affecting the PK/PD of the liposomal formulation of drugs and to elucidate the mechanisms underlying the variability in the PK/PD of liposomal drugs. In this review article, we describe the characteristics of liposome formulations and discuss the effects of various factors, including liposome-associated factors, host-associated factors, and treatment on the PK/PD of liposomal agents.
引用
收藏
页码:177 / 192
页数:16
相关论文
共 127 条
  • [1] LIPOSOME DISPOSITION INVIVO .3. DOSE AND VESICLE-SIZE EFFECTS
    ABRA, RM
    HUNT, CA
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1981, 666 (03) : 493 - 503
  • [2] Factors affecting the clearance and biodistribution of polymeric nanoparticles
    Alexis, Frank
    Pridgen, Eric
    Molnar, Linda K.
    Farokhzad, Omid C.
    [J]. MOLECULAR PHARMACEUTICS, 2008, 5 (04) : 505 - 515
  • [3] Allen Theresa M., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P513, DOI 10.2174/187152006778699121
  • [5] PHARMACOKINETICS OF STEALTH VERSUS CONVENTIONAL LIPOSOMES - EFFECT OF DOSE
    ALLEN, TM
    HANSEN, C
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1068 (02) : 133 - 141
  • [6] ALLEN TM, 1985, RES COMMUN CHEM PATH, V50, P281
  • [7] Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma
    Amantea, MA
    Forrest, A
    Northfelt, DW
    Mamelok, R
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (03) : 301 - 311
  • [8] Release of Liposomal Contents by Cell-Secreted Matrix Metalloproteinase-9
    Banerjee, Jayati
    Hanson, Andrea J.
    Gadam, Bhushan
    Elegbede, Adekunle I.
    Tobwala, Shakila
    Ganguly, Bratati
    Wagh, Anil V.
    Muhonen, Wallace W.
    Law, Benedict
    Shabb, John B.
    Srivastava, D. K.
    Mallik, Sanku
    [J]. BIOCONJUGATE CHEMISTRY, 2009, 20 (07) : 1332 - 1339
  • [9] Batist Gerald, 2002, Expert Opin Pharmacother, V3, P1739, DOI 10.1517/14656566.3.12.1739
  • [10] The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin
    Berry, G
    Billingham, M
    Alderman, E
    Richardson, P
    Torti, F
    Lum, B
    Patek, A
    Martin, FJ
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (07) : 711 - 716